Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Gilead Sciences Inc. | TRODELVY (sacituzumab govitecan-hziy) - (ASCENT-07) | Refractory metastatic triple-negative breast cancer (TNBC) | Phase 3 | Data Released | Intravenous | Oncology |
| Gilead Sciences Inc. | Lenacapavir - (PURPOSE 2) | HIV PreP | Phase 3 | Data Released | Subcutaneous injection | Anti-HIV |
| Gilead Sciences Inc. | Filgotinib - (PENGUIN) | Psoriatic arthritis | Phase 3 | Trial Discontinued | Oral | Immunology: Anti-TNF |
| Gilead Sciences Inc. | Islatravir (MK-8591D) and Lenacapavir - (ISLEND) | Human immunodeficiency virus (HIV) | Phase 3 | Ongoing | Oral | Anti-HIV |
| Gilead Sciences Inc. | Cilofexor (GS-9674) and firsocostat (GS-0976) - (ATLAS) | Nonalcoholic steatohepatitis (NASH) | Phase 2 | Trial Completed | Oral | Gastroenterology |
| Gilead Sciences Inc. | Seladelpar | Non-alcoholic steatohepatitis (NASH) | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
| Gilead Sciences Inc. | Domvanalimab (AB154) + Zimberelimab (AB122) - (ARC-7) | Non-small cell lung cancer (NSCLC) | Phase 2 | Ongoing | Intravenous | Oncology |
| Gilead Sciences Inc. | Filgotinib and GS-9876 | Sjogren’s syndrome | Phase 2 | Trial Completed | Oral | Immunology |
